A clinical-stage biopharmaceutical firm leveraging its KERO-100 platform to develop novel treatments for rare diseases with a strong cash position but negative operating income.
Investors may be attracted by the substantial cash reserves exceeding half a billion dollars, providing a long runway to advance multiple late-stage assets without immediate need for dilutive fundraising. The company's focus on rare diseases offers potential for high-margin products with limited competition if clinical trials succeed and regulatory approvals are obtained. A successful transition from clinical to commercial phases could unlock significant value given the orphan drug incentives available in this sector.
The negative trend in net income, worsening from -$104.7M in 2022 to -$187.4M in 2024, signals increasing financial pressure and high burn rates typical of pre-revenue biotechs. With revenue growth slowing and operating profits deeply negative at -$210.8M, the company lacks current profitability and relies entirely on external capital markets. Any setback in clinical trials for its key programs could jeopardize the entire business model given the lack of diversified revenue streams.
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare diseases using its proprietary KERO-100 platform. The company primarily serves the orphan drug market with late-stage programs targeting conditions like pulmonary arterial hypertension and other rare disorders. Financial data indicates significant investment in research and development, characterized by minimal revenue generation typical of pre-commercial biotech firms.
The company reported a net loss of $187.4M in 2024, driven primarily by substantial research and development expenditures of $173.6M aimed at advancing its pipeline assets. Despite this heavy investment, the firm maintained a robust cash position ending at $561.4M, reflecting successful financing activities that offset operational burn. Operating expenses totaled $214.4M, with general and administrative costs reaching $40.8M, highlighting the capital-intensive nature of its clinical-stage operations.
The biopharmaceutical industry for rare diseases is characterized by high R&D costs, long development timelines, and reliance on government incentives like orphan drug exclusivity periods. Companies in this space often operate with minimal revenue until clinical trials succeed, requiring significant investor patience and capital efficiency. Success depends heavily on navigating complex regulatory pathways while managing the high risk of clinical trial failure inherent in novel therapeutic modalities.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $151.0K | $3.5M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $151.0K | $3.5M |
| Operating Expenses | $114.8M | $170.1M | $214.4M |
| Operating Income | $-114.8M | $-169.9M | $-210.8M |
| R&D | $87.3M | $135.3M | $173.6M |
| G&A | $27.5M | $34.8M | $40.8M |
| Stock-Based Comp | $18.7M | $28.8M | $34.9M |
| Depreciation | $674.0K | $815.0K | $1.2M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $10.1M | $16.9M | $23.8M |
| Pre-Tax Income | $-104.7M | $-153.0M | $-187.1M |
| Income Tax | $0 | $0 | $300.0K |
| Continuing Ops | $-104.7M | $-153.0M | $-187.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-104.7M | $-153.0M | $-187.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-104.7M | $-153.0M | $-187.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $285.8M | $347.3M | $588.9M |
| Cash & Equivalents | $279.0M | $331.1M | $559.9M |
| Accounts Receivable | $0 | $143.0K | $2.7M |
| Prepaid Expenses | $6.7M | $16.0M | $26.2M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $21.0M | $22.7M | $27.0M |
| PP&E (Net) | $2.0M | $4.1M | $4.2M |
| Operating Leases | $15.5M | $15.3M | $19.3M |
| Other LT Assets | $3.4M | $3.3M | $3.5M |
| Total Assets | $306.8M | $370.0M | $615.9M |
| Current Liabilities | $16.5M | $24.4M | $27.4M |
| Accounts Payable | $3.3M | $5.5M | $4.6M |
| Current Leases | $455.0K | $1.0M | $2.0M |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $12.8M | $13.4M | $16.9M |
| LT Operating Leases | $12.8M | $13.4M | $16.9M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $29.4M | $37.8M | $44.3M |
| Shareholders' Equity | $277.4M | $332.2M | $571.6M |
| Paid-In Capital | $505.9M | $713.6M | $1.14B |
| Retained Earnings | $-228.4M | $-381.4M | $-568.8M |
| Total L&E | $306.8M | $370.0M | $615.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-104.7M | $-153.0M | $-187.4M |
| Non-Cash Adjustments | $42.8M | $11.7M | $11.0M |
| Working Capital Changes | $-8.2M | $16.8M | $15.5M |
| Cash from Operations | $-70.1M | $-124.5M | $-160.9M |
| Capital Expenditures | $1.2M | $2.5M | $1.9M |
| Cash from Investing | $-1.2M | $-2.5M | $-1.9M |
| Cash from Financing | $120.3M | $179.0M | $391.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $49.0M | $52.0M | $229.0M |
| Beginning Cash | $231.4M | $280.4M | $332.4M |
| Ending Cash | $280.4M | $332.4M | $561.4M |
Orphan Drug Development Programs focusing on Pulmonary Arterial Hypertension and other rare disease indications; Platform Technology Licensing utilizing the KERO-100 discovery engine; Intellectual Property Monetization through potential future partnerships or acquisitions of developed assets.
Clinical trial failures or delays could eliminate significant R&D investments given the high cost of developing rare disease therapies; Reliance on external funding sources due to negative operating cash flow and expanding accumulated deficit; Regulatory hurdles specific to orphan drug approval processes which can be unpredictable and time-consuming; Potential dilution from equity offerings if cash reserves are depleted before product commercialization.
Proprietary KERO-100 platform enabling rapid identification of novel targets for rare diseases with high unmet medical need; Strong balance sheet with over $559M in cash providing substantial runway for R&D without immediate dilution pressure; Strategic focus on orphan drugs which often qualify for regulatory incentives and extended market exclusivity.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.